Cited by 197Liver Disease Diagnosis and TreatmentLiver Disease and TransplantationLiver Diseases and Immunity

The DOI matches its Crossref record; 32 of the 34 references it cites were found in a registry or an index.

Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver Disease

Open access

Petta, Salvatore, Sebastiani, Giada, Viganò, Mauro, Ampuero, Javier, Wai-Sun Wong, Vincent, Boursier, Jerome, Berzigotti, Annalisa, Bugianesi, Elisabetta, Fracanzani, Anna Ludovica, Cammà, Calogero, Enea, Marco, Grottes, Marraud des, Di Marco, Vito, Younes, Ramy, Keyrouz, Aline, Mazzola, Sergio, Mendoza, Yuly, Pennisi, Grazia, Romero-Gomez, Manuel, Craxì, Antonio, de Ledinghen, Victor·2021·Clinical Gastroenterology and Hepatology

DOI 10.1016/j.cgh.2020.06.045

Open this paper in CoChat — free account Open PDF

Abstract

Background & aims Patients with advanced fibrosis related to nonalcoholic fatty liver disease (NAFLD) are at risk of developing hepatic and extrahepatic complications. We investigated whether, in a large cohort of patients with NAFLD and compensated advanced chronic liver disease, baseline liver stiffness measurements (LSMs) and their changes can be used to identify patients at risk for liver-related and extrahepatic events.Methods We performed a retrospective analysis of consecutive patients with NAFLD (n = 1039) with a histologic diagnosis of F3-F4 fibrosis and/or LSMs>10 kPa, followed for at least 6 months, from medical centers in 6 countries. LSMs were made by FibroScan using the M or XL probe and recorded at baseline and within 1 year from the last follow-up examination. Differences between follow up and baseline LSMs were categorized as: improvement (reduction of more than 20%), stable (reduction of 20% to an increase of 20%), impairment (an increase of 20% or more). We recorded hepatic events (such as liver decompensation, ascites, encephalopathy, variceal bleeding, jaundice, or hepatocellular carcinoma [HCC]) and overall and liver-related mortality during a median follow-up time of 35 months (interquartile range, 19-63 months).Results Based on Cox regression analysis, baseline LSM was independently associated with occurrence of hepatic decompensation (hazard ratio [HR], 1.03; 95% CI, 1.02-1.04; P < .001), HCC (HR, 1.03; 95% CI, 1.00-1.04; P = .003), and liver-related death (HR, 1.02; 95% CI, 1.02-1.03; P = .005). In 533 patients with available LSMs during the follow-up period, change in LSM was independently associated with hepatic decompensation (HR, 1.56; 95% CI, 1.05-2.51; P = .04), HCC (HR, 1.72; 95% CI, 1.01-3.02; P = .04), overall mortality (HR, 1.73; 95% CI, 1.11-2.69; P = .01), and liver-related mortality (HR, 1.96; 95% CI, 1.10-3.38; P = .02).Conclusions In patients with NAFLD and compensated advanced chronic liver disease, baseline LSM and change in LSM are associated with risk of liver-related events and mortality.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.cgh.2020.06.045

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Management of Hepatocellular Carcinoma *
Bruix, J., & Sherman, M. (2005) · Hepatology · doi:10.1002/hep.20933 · Cited by 5,913
Expanding consensus in portal hypertension
de Franchis, R. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.05.022 · Cited by 3,078
Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease
Angulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis
Vilar-Gomez, E., Martinez-Perez, Y., Calzadilla-Bertot, L., Torres-Gonzalez, A., Gra-Oramas, B., Gonzalez-Fabian, L., Friedman, S. L., Diago, M., & Romero-Gomez, M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.005 · Cited by 2,492
Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up
Ekstedt, M., Hagström, H., Nasr, P., Fredrikson, M., Stål, P., Kechagias, S., & Hultcrantz, R. (2015) · Hepatology · doi:10.1002/hep.27368 · Cited by 2,287
The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis
Younossi, Z. M., Golabi, P., de Avila, L., Paik, J. M., Srishord, M., Fukui, N., Qiu, Y., Burns, L., Afendy, A., & Nader, F. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.06.021 · Cited by 2,235
Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030
Estes, C., Anstee, Q. M., Arias, M., Bantel, H., Bellentani, S., Caballería, J., Colombo, M., Craxì, A., Crespo, J., Day, C. P., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.05.036 · Cited by 2,046

Show all 34 references

Research works printed but not linked: 5

Shili-Masmoudi, 2020, Liver stiffness measurement predicts long-term survival and complications in non-alcoholic fatty liver disease, Liver Int, 40, 581, 10.1111/liv.14301 · DOI
2000, American Diabetes Association: Clinical Practice Recommendations 2000 Committee Report, Diabetes Care, 23, S4
de Franchis, 2015, Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension, J Hepatol, 63, 743, 10.1016/j.jhep.2015.05.022 · DOI · Paper page
Cillo, 2015, A Multistep, Consensus-Based Approach to Organ Allocation in Liver Transplantation: Toward a "Blended Principle Model", Am J Transplant, 15, 2552, 10.1111/ajt.13408 · DOI
Boursier, 2013, Determination of reliability criteria for liver stiffness evaluation by transient elastography, Hepatology, 57, 1182, 10.1002/hep.25993 · DOI · Paper page

Sorted by citations

AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease
Rinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., Kleiner, D. E., & Loomba, R. (2023) · Hepatology · doi:10.1097/hep.0000000000000323 · Cited by 2,667
EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).
Tacke, F., Horn, P., Wai-Sun Wong, V., Ratziu, V., Bugianesi, E., Francque, S., Zelber-Sagi, S., Valenti, L., Roden, M., Schick, F., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.04.031 · Cited by 2,210
EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update
Berzigotti, A., Tsochatzis, E., Boursier, J., Castera, L., Cazzagon, N., Friedrich-Rust, M., Petta, S., & Thiele, M. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.05.025 · Cited by 1,925
AASLD Practice Guidance on risk stratification and management of portal hypertension and varices in cirrhosis
Kaplan, D. E., Ripoll, C., Thiele, M. S., Fortune, B. E., Simonetto, D. A., García–Tsao, G., & Bosch, J. (2023) · Hepatology · doi:10.1097/hep.0000000000000647 · Cited by 549
EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
(2024) · Obesity Facts · doi:10.1159/000539371 · Cited by 545
Challenges and opportunities in NASH drug development
Harrison, S. A., Allen, A. M., Dubourg, J., Noureddin, M., & Alkhouri, N. (2023) · Nature Medicine · doi:10.1038/s41591-023-02242-6 · Cited by 353
Low Accuracy of FIB-4 and NAFLD Fibrosis Scores for Screening for Liver Fibrosis in the Population
Graupera, I., Thiele, M. S., Serra‐Burriel, M., Caballería, L., Roulot, D. M., Wong, G. L., Fabrellas, N., Guha, I. N., Arslanow, A., Expósito, C., et al. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.12.034 · Cited by 302
Metabolic dysfunction-associated steatotic liver disease in adults
Huang, D. Q., Wong, V. W., Rinella, M. E., Boursier, J., Lazarus, J. V., Yki‐Järvinen, H., & Loomba, R. S. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00599-1 · Cited by 365
Natural history and progression of metabolic dysfunction-associated steatotic liver disease
Hagström, H., Shang, Y., Hegmar, H., & Nasr, P. (2024) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(24)00193-6 · Cited by 310
AGA clinical practice update on the role of noninvasive biomarkers in the evaluation and management of nonalcoholic fatty liver disease: expert review
Wattacheril, J. J., Abdelmalek, M. F., Lim, J. K., & Sanyal, A. J. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.06.013 · Cited by 236
Imaging biomarkers of NAFLD, NASH, and fibrosis
Ajmera, V. H., & Loomba, R. S. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101167 · Cited by 214
High Prevalence of Advanced Liver Fibrosis Assessed by Transient Elastography Among U.S. Adults With Type 2 Diabetes
Ciardullo, S., Monti, T., & Perseghin, G. (2020) · Diabetes Care · doi:10.2337/dc20-1778 · Cited by 196
The first MASH drug therapy on the horizon: Current perspectives of resmetirom
Petta, S., Targher, G., Romeo, S., Pajvani, U. B., Zheng, M., Aghemo, A., & Valenti, L. V. C. (2024) · Liver International · doi:10.1111/liv.15930 · Cited by 182
The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease
Eslam, M., Fan, J., Yu, M., Wong, V. W., Cua, I. H., Liu, C., Tanwandee, T., Gani, R. A., Seto, W., Alam, S., et al. (2025) · Hepatology International · doi:10.1007/s12072-024-10774-3 · Cited by 200
Expert Panel Recommendations: Practical Clinical Applications for Initiating and Monitoring Resmetirom in Patients With MASH/NASH and Moderate to Noncirrhotic Advanced Fibrosis
Noureddin, M., Charlton, M., Harrison, S. A., Bansal, M. B., Alkhouri, N., Loomba, R. S., Sanyal, A. J., & Rinella, M. E. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.07.003 · Cited by 170
AASLD Practice Guideline on blood-based noninvasive liver disease assessment of hepatic fibrosis and steatosis
Sterling, R. K., Patel, K., Duarte‐Rojo, A., Asrani, S. K., Alsawas, M., Dranoff, J. A., Fiel, M. I., Murad, M. H., Leung, D. H., Levine, D., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000000845 · Cited by 188
Non-invasive diagnosis and monitoring of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
Tincopa, M. A., & Loomba, R. S. (2023) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(23)00066-3 · Cited by 163
Noninvasive assessment of liver fibrosis in NAFLD
Sanyal, A. J., Castera, L., & Wong, V. W.-S. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.03.042 · Cited by 157
WFUMB Guideline/Guidance on Liver Multiparametric Ultrasound: Part 1. Update to 2018 Guidelines on Liver Ultrasound Elastography
Ferraioli, G., Barr, R. G., Berzigotti, A., Sporea, I., Wong, V. W., Reiberger, T., Karlas, T., Thiele, M. S., Cardoso, A. C., Ayonrinde, O. T., et al. (2024) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2024.03.013 · Cited by 160
Liver Stiffness on Magnetic Resonance Elastography and the MEFIB Index and Liver-Related Outcomes in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Individual Participants
Ajmera, V. H., Kim, B. K., Yang, K. Y., Majzoub, A. M., Nayfeh, T., Tamaki, N., Izumi, N., Nakajima, A., Idılman, R., Gümüşsoy, M., et al. (2022) · Gastroenterology · doi:10.1053/j.gastro.2022.06.073 · Cited by 141
Clinical Trial Landscape in NASH
Harrison, S. A., Loomba, R. S., Dubourg, J., Ratziu, V., & Noureddin, M. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.03.041 · Cited by 142
Noninvasive Assessment of Liver Fibrosis
Castéra, L., Rinella, M. E., & Tsochatzis, E. A. (2025) · New England Journal of Medicine · doi:10.1056/nejmra2403308 · Cited by 120
Dynamics in Liver Stiffness Measurements Predict Outcomes in Advanced Chronic Liver Disease
Semmler, G., Yang, Z., Fritz, L., Köck, F., Hofer, B., Balcar, L., Hartl, L., Jachs, M., Stopfer, K., Schedlbauer, A., et al. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.06.030 · Cited by 110
Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis
Loomba, R., Huang, D. Q., Sanyal, A. J., Anstee, Q. M., Trauner, M., Lawitz, E. J., Ding, D., Ma, L., Jia, C., Billin, A., et al. (2023) · Gut · doi:10.1136/gutjnl-2022-327777 · Cited by 110
Increases and decreases in liver stiffness measurement are independently associated with the risk of liver-related events in NAFLD
Gawrieh, S., Vilar-Gomez, E., Wilson, L. A., Pike, F., Kleiner, D. E., Neuschwander-Tetri, B. A., Diehl, A. M., Dasarathy, S., Kowdley, K. V., Hameed, B., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.05.008 · Cited by 94
AGILE 3+ Score for the Diagnosis of Advanced Fibrosis and for Predicting Liver-related Events in NAFLD
Pennisi, G., Enea, M., Pandolfo, A., Celsa, C., Antonucci, M., Ciccioli, C., Infantino, G., Mantia, C. L., Parisi, S., Tulone, A., et al. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2022.06.013 · Cited by 90
Envisioning how to advance the MASH field
Allen, A. M., Younossi, Z. M., Diehl, A. M., Charlton, M., & Lazarus, J. V. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-00938-9 · Cited by 64
KASL clinical practice guidelines for noninvasive tests to assess liver fibrosis in chronic liver disease
Kim, M. N., Han, J. W., An, J., Kim, B. K., Jin, Y., Kim, S., Lee, M., Lee, H. A., Cho, Y., Kim, H. Y., et al. (2024) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0506 · Cited by 65
Noninvasive assessment of liver fibrosis and its clinical significance in nonalcoholic fatty liver disease
Tamaki, N., Kurosaki, M., Huang, D. Q., & Loomba, R. S. (2022) · Hepatology Research · doi:10.1111/hepr.13764 · Cited by 62
Noninvasive imaging biomarkers for liver fibrosis in nonalcoholic fatty liver disease: current and future
Yu, J. H., Lee, H. A., & Kim, S. U. (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0436 · Cited by 61
Emerging role of statin therapy in the prevention and management of cirrhosis, portal hypertension, and HCC
Sharpton, S. R., & Loomba, R. S. (2023) · Hepatology · doi:10.1097/hep.0000000000000278 · Cited by 62
Using liver stiffness to predict and monitor the risk of decompensation and mortality in patients with alcohol-related liver disease
Thorhauge, K. H., Semmler, G., Johansen, S., Lindvig, K. P., Kjærgaard, M., Hansen, J. K., Torp, N., Hansen, C. D., Andersen, P., Hofer, B., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.02.019 · Cited by 52
Point-of-Care Noninvasive Prediction of Liver-Related Events in Patients With Nonalcoholic Fatty Liver Disease
Pons, M., Rivera‐Esteban, J., Ma, M. M., Davyduke, T., Delamarre, A., Hermabessière, P., Dupuy, J., Wong, G. L., Yip, T. C., Pennisi, G., et al. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.08.004 · Cited by 50
Risk for hepatic and extra-hepatic outcomes in nonalcoholic fatty liver disease
Hagström, H., Kechagias, S., & Ekstedt, M. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13343 · Cited by 52
Prognostic impact of liver fibrosis and steatosis by transient elastography for cardiovascular and mortality outcomes in individuals with nonalcoholic fatty liver disease and type 2 diabetes: the Rio de Janeiro Cohort Study
Cardoso, C. R. L., Villela‐Nogueira, C. A., Leite, N. C., & Salles, G. F. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01388-2 · Cited by 52
CAP and LSM as determined by VCTE are independent predictors of all-cause mortality in the US adult population
Gómez, E. V., Vuppalanchi, R., Gawrieh, S., Samala, N. R., & Chalasani, N. (2023) · Hepatology · doi:10.1097/hep.0000000000000023 · Cited by 44
AASLD Practice Guideline on noninvasive liver disease assessment of portal hypertension
Sterling, R. K., Asrani, S. K., Levine, D., Duarte‐Rojo, A., Patel, K., Fiel, M. I., Leung, D. H., Taouli, B. A., Alsawas, M., Murad, M. H., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000000844 · Cited by 47
Dynamics of Liver Stiffness Measurement and Clinical Course of Primary Biliary Cholangitis
Lam, L., Soret, P., Lemoinne, S., Hansen, B. E., Hirschfield, G. M., Gulamhusein, A. F., Montaño‐Loza, A. J., Lytvyak, E., Parés, A. R., Olivas, I., et al. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.06.035 · Cited by 44
An updated overview on hepatocellular carcinoma in patients with Metabolic dysfunction-Associated Steatotic Liver Disease: Trends, pathophysiology and risk-based surveillance
Armandi, A., Rosso, C., Caviglia, G. P., & Bugianesi, E. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156080 · Cited by 47
Predicting Liver‐Related Outcomes in People With Nonalcoholic Fatty Liver Disease: The Prognostic Value of Noninvasive Fibrosis Tests
Johnson, A. L., Hayward, K. L., Patel, P. J., Horsfall, L. U., Cheah, A. E. Z., Irvine, K. M., Russell, A. W., Stuart, K. A., Williams, S. R., Härtel, G., et al. (2021) · Hepatology Communications · doi:10.1002/hep4.1852 · Cited by 41
Surveillance of the liver in type 2 diabetes: important but unfeasible?
Qadri, S. U., & Yki‐Järvinen, H. (2024) · Diabetologia · doi:10.1007/s00125-024-06087-7 · Cited by 45
Comparing serial and current liver stiffness measurements to predict decompensation in compensated advanced chronic liver disease patients
Wong, Y. J., Chen, V. L., Abdulhamid, A., Tosetti, G., Navadurong, H., Kaewdech, A., Cristiu, J., Song, M. W., Devan, P., Tiong, K. L. A., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000000891 · Cited by 40
Non-Invasive Measurement of Hepatic Fibrosis by Transient Elastography: A Narrative Review
Rinaldi, L., Giorgione, C., Mormone, A., Esposito, F., Rinaldi, M., Berretta, M., Marfella, R., & Romano, C. P. (2023) · Viruses · doi:10.3390/v15081730 · Cited by 44
Non-invasive tools for compensated advanced chronic liver disease and portal hypertension after Baveno VII – an update
Segna, D., Mendoza, Y. P., Lange, N. F., Rodrigues, S. G., & Berzigotti, A. (2022) · Digestive and Liver Disease · doi:10.1016/j.dld.2022.10.009 · Cited by 38
Prognostic utility of magnetic resonance elastography and MEFIB index in predicting liver-related outcomes and mortality in individuals at risk of and with nonalcoholic fatty liver disease
Ajmera, V. H., Nguyen, K., Tamaki, N., Sharpton, S. R., Bettencourt, R., & Loomba, R. S. (2022) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848221093869 · Cited by 37
Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO)
Marchesini, G., Bugianesi, E., Burra, P., Marra, F., Miele, L., Alisi, A., Vajro, P., Masarone, M., Petta, S., Persico, M., et al. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.04.028 · Cited by 70
Liver fibrosis in nonalcoholic fatty liver disease patients: noninvasive evaluation and correlation with cardiovascular disease and mortality
Ballestri, S., Mantovani, A., Girolamo, M. D., Baldelli, E., Capitelli, M., & Lonardo, A. (2023) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2022.23 · Cited by 33
Post-treatment LSM rather than change during treatment predicts decompensation in patients with cACLD after HCV cure
Semmler, G., López, S. A., Pons, M., Lens, S., Dajti, E., Griemsmann, M., Zanetto, A., Burghart, L., Hametner‐Schreil, S., Hartl, L., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.03.015 · Cited by 34
Liver stiffness progression in biopsy-proven metabolic dysfunction–associated steatotic disease among people with diabetes versus people without diabetes: A prospective multicenter study
Huang, D. Q., Wilson, L., Behling, C. A., Amangurbanova, M., Kleiner, D. E., Kowdley, K. V., Dasarathy, S., Terrault, N. A., Diehl, A. M., Chalasani, N., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000001015 · Cited by 39
Screening for compensated advanced chronic liver disease using refined Baveno VI elastography cutoffs in Asian patients with nonalcoholic fatty liver disease
Zhou, Y., Gao, F., Liu, W., Wong, G. L., Mahadeva, S., Mustapha, N. R. N., Wang, X., Chan, W., Wong, V. W., & Zheng, M. (2021) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16487 · Cited by 34
Brazilian evidence-based guideline for screening, diagnosis, treatment, and follow-up of metabolic dysfunction-associated steatotic liver disease (MASLD) in adult individuals with overweight or obesity: A joint position statement from the Brazilian Society of Endocrinology and Metabolism (SBEM), Brazilian Society of Hepatology (SBH), and Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso)
Moreira, R. O., Valério, C. M., Villela‐Nogueira, C. A., Cercato, C., Gerchman, F., Lottenberg, A. M., Godoy‐Matos, A. F., Oliveira, R. D. A., Brandão‐Mello, C. E., Álvares‐da‐Silva, M. R., et al. (2023) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-4292-2023-0123 · Cited by 45
Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO)
Marchesini, G., Bugianesi, E., Burra, P., Marra, F., Miele, L., Alisi, A., Vajro, P., Masarone, M., Petta, S., Persico, M., et al. (2021) · Digestive and Liver Disease · doi:10.1016/j.dld.2021.04.029 · Cited by 34
Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver disease
Wang, Y., Song, S. J., Jiang, Y., Lai, J. C., Wong, G. L., Wong, V. W., & Yip, T. C. (2024) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0246 · Cited by 32
Emerging therapies and real-world application of metabolic dysfunction-associated steatotic liver disease treatment
Kim, H. Y., & Rinella, M. E. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2025.0083 · Cited by 36
Nonheavy Alcohol Use Associates With Liver Fibrosis and Nonalcoholic Steatohepatitis in the Framingham Heart Study
Rice, B. A., Naimi, T. S., & Long, M. T. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2022.10.039 · Cited by 32
Aramchol improves hepatic fibrosis in metabolic dysfunction–associated steatohepatitis: Results of multimodality assessment using both conventional and digital pathology
Ratziu, V., Yilmaz, Y. N., Lazas, D. J., Friedman, S. L., Lackner, C., Behling, C. A., Cummings, O. W., Chen, L., Petitjean, M. M., Gilgun‐Sherki, Y., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000000980 · Cited by 31
Usefulness of Different Imaging Modalities in Evaluation of Patients with Non-Alcoholic Fatty Liver Disease
Grąt, K., Grąt, M., & Rowiński, O. (2020) · Biomedicines · doi:10.3390/biomedicines8090298 · Cited by 28
Evolving portal hypertension through Baveno VII recommendations
Mendizábal, M., Cançado, G. G. L., & Albillos, A. (2023) · Annals of Hepatology · doi:10.1016/j.aohep.2023.101180 · Cited by 29
Liver fibrosis as a barometer of systemic health by gauging the risk of extrahepatic disease
Lonardo, A., Ballestri, S., Baffy, G., & Weiskirchen, R. (2024) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2024.42 · Cited by 29
Accuracy of FIB-4 to Detect Elevated Liver Stiffness Measurements in Patients with Non-Alcoholic Fatty Liver Disease: A Cross-Sectional Study in Referral Centers
Viganò, M., Pugliese, N., Cerini, F., Turati, F., Cimino, V., Ridolfo, S., Rocchetto, S., Foglio, F., Terrin, M., Vecchia, C. L., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012489 · Cited by 27
NAFLD No More: A Review of Current Guidelines in the Diagnosis and Evaluation of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Kaylan, K. B., & Paul, S. (2024) · Current Diabetes Reports · doi:10.1007/s11892-024-01558-y · Cited by 27
Diagnosis and non‐invasive assessment of MASLD in type 2 diabetes and obesity
Chan, W., Petta, S., Noureddin, M., Goh, G. B., & Wong, V. W. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17866 · Cited by 25
Magnetic resonance elastography-based prediction model for hepatic decompensation in NAFLD: A multicenter cohort study
Kim, B. K., Bergstrom, J., Loomba, R., Tamaki, N., Izumi, N., Nakajima, A., Idılman, R., Gümüşsoy, M., Öz, D. K., Erden, A., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000470 · Cited by 24
MEFIB‐Index and MAST‐Score in the assessment of hepatic decompensation in metabolic dysfunction‐associated steatosis liver disease—Individual participant data meta‐analyses
Noureddin, N., Ajmera, V. H., Bergstrom, J., Bettencourt, R., Huang, D. Q., Siddiqi, H., Majzoub, A. M., Nayfeh, T., Tamaki, N., Izumi, N., et al. (2023) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17707 · Cited by 24
Monitoring disease progression in metabolic dysfunction‐associated steatotic liver disease
Noureddin, N., Copur‐Dahi, N., & Loomba, R. S. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17752 · Cited by 25
Update on the diagnosis and management of portal hypertension in cirrhosis according to the Baveno VII Consensus Conference recommendations
Téllez, L., Guerrero, A. F., & Albillos, A. (2022) · Revista Española de Enfermedades Digestivas · doi:10.17235/reed.2022.8868/2022 · Cited by 21
Risk of liver-related events in metabolic dysfunction–associated steatohepatitis (MASH) patients with fibrosis: A comparative analysis of various risk stratification criteria
Pennisi, G., Enea, M., Romero‐Gómez, M., Bugianesi, E., Wong, V. W., Fracanzani, A. L., de Lédinghen, V., George, J., Berzigotti, A., Viganò, M., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000616 · Cited by 22
Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO)
Associazione Italiana per lo Studio del Fegato (AISF), S. I. D. D. (. A. S. I. D. (. (2021) · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity · doi:10.1007/s40519-021-01287-1 · Cited by 22
Use of liver stiffness measurement for HCC risk stratification in metabolic dysfunction–associated steatotic liver disease
John, B. V., Bastaich, D., Deng, Y., Singal, A. G., Dahman, B. A., & on behalf of the Veterans Analysis of Liver Disease (VALID) group of investigators (2025) · Hepatology · doi:10.1097/hep.0000000000001498 · Cited by 20
A Novel SAVE Score to Stratify Decompensation Risk in Compensated Advanced Chronic Liver Disease (CHESS2102): An International Multicenter Cohort Study
Liu, C., Cao, Z., Yan, H., Wong, Y. J., Xie, Q., Hirooka, M., Enomoto, H., Kim, T. H., Hanafy, A. S., Liu, Y., et al. (2022) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001873 · Cited by 20
Prediction of outcomes in patients with metabolic dysfunction-associated steatotic liver disease based on initial measurements and subsequent changes in magnetic resonance elastography
Kobayashi, T., Iwaki, M., Nogami, A., Kawamura, N., Honda, Y., Ogawa, Y., Imajo, K., Yoneda, M., Saito, S., & Nakajima, A. (2023) · Journal of Gastroenterology · doi:10.1007/s00535-023-02049-9 · Cited by 21
Understanding MASH: An Examination of Progression and Clinical Outcomes by Disease Severity in the TARGET-NASH Database
Luthra, R., & Sheth, A. (2024) · Advances in Therapy · doi:10.1007/s12325-024-03085-4 · Cited by 21
Approaches to the Diagnosis of Portal Hypertension: Non-Invasive or Invasive Tests?
Dajti, E., Alemanni, L. V., Marasco, G., Montagnani, M., & Azzaroli, F. (2021) · Hepatic Medicine Evidence and Research · doi:10.2147/hmer.s278077 · Cited by 18
Metabolic dysfunction associated steatotic liver disease: Current practice, screening guidelines and management in the primary care setting
Gupta, U., Ruli, T. M., Buttar, D., Shoreibah, M., & Gray, M. E. (2023) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2023.11.007 · Cited by 19
Noninvasive Tests (NITs) for Hepatic Fibrosis in Fatty Liver Syndrome
Han, M. A. T. (2020) · Life · doi:10.3390/life10090198 · Cited by 17
Liver stiffness measurement identifies subclinical myocardial dysfunction in non-advanced non-alcoholic fatty liver disease patients without overt heart disease
Sonaglioni, A., Cerini, F., Cerrone, A., Argiento, L., Nicolosi, G. L., Rigamonti, E., Lombardo, M., Rumi, M. G., & Viganò, M. (2022) · Internal and Emergency Medicine · doi:10.1007/s11739-022-02966-2 · Cited by 17
Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD) after Liver Transplantation: A Narrative Review of an Emerging Issue
Savino, A., Loglio, A., Neri, F., Camagni, S., PASULO, L., Lucà, M. G., Trevisan, R., FAGIUOLI, S., & Viganò, M. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13133871 · Cited by 15
The ANTICIPATE-NASH Models Stratify Better the Risk of Clinical Events Than Histology in Metabolic Dysfunction-Associated Steatotic Liver Disease Patients With Advanced Chronic Liver Disease
Aceituno, L., Bañares, J., Pons, M., Rivera‐Esteban, J., Sabiote, C., Cammà, C., Ciancimino, G., Pennisi, G., Tulone, A., Ma, M. M., et al. (2025) · Gastroenterology · doi:10.1053/j.gastro.2025.08.020 · Cited by 16
The associations between fibrosis changes and liver‐related events in patients with metabolic dysfunction‐associated steatotic liver disease
Lee, H. W., Kim, K. H., Ahn, S. H., Lee, H. C., & Choi, J. (2024) · Liver International · doi:10.1111/liv.15897 · Cited by 14
A cholestatic pattern predicts major liver‐related outcomes in patients with non‐alcoholic fatty liver disease
Pennisi, G., Pipitone, R. M., Cabibi, D., Enea, M., Romero‐Gómez, M., Viganò, M., Bugianesi, E., Wong, V. W., Fracanzani, A. L., Sebastiani, G., et al. (2022) · Liver International · doi:10.1111/liv.15232 · Cited by 13
Exploring Opportunities to Enhance the Screening and Surveillance of Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease (NAFLD) through Risk Stratification Algorithms Incorporating Ultrasound Elastography
Țâru, M.-G., & Lupșor‐Platon, M. (2023) · Cancers · doi:10.3390/cancers15164097 · Cited by 13
Global patterns of utilization of noninvasive tests for the clinical management of metabolic dysfunction–associated steatotic liver disease
Allen, A. M., Lazarus, J. V., Alkhouri, N., Noureddin, M., Wong, V. W., Tsochatzis, E. A., de Avila, L., Racila, A., Nader, F., Mark, H. E., et al. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000678 · Cited by 12
Noninvasive Tests to Assess Fibrosis and Disease Severity in Metabolic Dysfunction-Associated Steatotic Liver Disease
Tincopa, M. A., & Loomba, R. S. (2024) · Seminars in Liver Disease · doi:10.1055/s-0044-1788277 · Cited by 12
Prevention of hepatocellular carcinoma and surveillance of high risk patients
Kaya, E., Mazzolini, G. D., Yilmaz, Y. N., & Canbay, A. E. (2021) · Hepatology forum/Hepatology forum (Online) · doi:10.14744/hf.2021.2021.0033 · Cited by 14
Non-Invasive Tests of Liver Fibrosis Help in Predicting the Development of Hepatocellular Carcinoma among Patients with NAFLD
Pons, M., Rivera‐Esteban, J., Manzano-Núñez, R., Bañares, J., Bermúdez, M., Vargas, V., Salcedo, M. T., Castells, L., Augustín, S., Mínguez, B., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11092466 · Cited by 13
Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Facts and Hopes
Adinolfi, L. E., Marrone, A., Izzi, A., & Craxì, A. (2025) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2025.103411 · Cited by 11
The Liver in Diabetes and Metabolic Syndrome
Mahmoud, M. C., & Abdelmalek, M. F. (2025) · Clinics in Liver Disease · doi:10.1016/j.cld.2025.04.003 · Cited by 14
Transient elastography in patients at risk of liver fibrosis in primary care: a follow-up study over 54 months
Reinson, T., Byrne, C. D., Patel, J., El-Gohary, M., & Moore, M. V. (2021) · BJGP Open · doi:10.3399/bjgpo.2021.0145 · Cited by 11
Low‐quality muscle mass rather than normal‐quality muscle mass determines fibrosis progression in biopsy‐proven NAFLD
Lee, Y. K., Koo, B. K., Joo, S. K., Lee, D. H., Jang, H., Chai, J. W., Lee, M. S., Jang, S. W., So, Y. H., Park, J. H., et al. (2023) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17601 · Cited by 11
Long-Term Effect of PNPLA3 on the Aggravation of Nonalcoholic Fatty Liver Disease in a Biopsy-Proven Cohort
Koo, B. K., Lee, H., Kwak, S., Lee, D. H., Park, J. H., & Kim, W. K. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2022.02.026 · Cited by 11
Prognostic significance of dynamic changes in liver stiffness measurement in patients with chronic hepatitis B and compensated advanced chronic liver disease
Yu, H., Huang, Y., Li, M., Jiang, H., Yang, B., Xi, X., Smayi, A., Wu, B., & Yang, Y. (2024) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16673 · Cited by 10
MAFLD but not MASLD increases risk of all-cause mortality in regional Australia, with components of metabolic syndrome exacerbating factors: 20 year longitudinal, cohort study
Vaz, K., Kemp, W. W., Majeed, A., Lubel, J. S., Magliano, D. J., Glenister, K., Bourke, L., Simmons, D. S., & Roberts, S. K. (2024) · Hepatology International · doi:10.1007/s12072-024-10748-5 · Cited by 11
Preventing the progression of cirrhosis to decompensation and death
Villanueva, C., Tripathi, D., & Bosch, J. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-01031-x · Cited by 13
Prediction of Liver-Related Events With a Combination of Liver Stiffness Measurements and Controlled Attenuation Parameters in Japanese Patients With Biopsy-Proven Non-alcoholic Fatty Liver Disease
Hayashi, H., Kamada, Y., Fujii, H., Takahashi, H., Oeda, S., Iwaki, M., Kawaguchi, T., Tomita, E., Yoneda, M., Tokushige, A., et al. (2023) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2023.03.023 · Cited by 10
The interplay between Helicobacter pylori infection and rs738409 PNPLA3 in metabolic dysfunction-associated steatotic liver disease
Maiorana, F., Neschuk, M., Caronia, M. V., Elizondo, K., Robledo, M. L., Schneider, A., Veron, G., Zapata, P. D., & Barreyro, F. J. (2024) · PLoS ONE · doi:10.1371/journal.pone.0310361 · Cited by 9
The role of noninvasive biomarkers for monitoring cell injury in advanced liver fibrosis
Righetti, R., Cinque, F., Patel, K., & Sebastiani, G. (2025) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2025.2450717 · Cited by 9
Managing MASLD Through Preventive Hepatology: Integrating Policy Reform, Public Health and Personalised Care
Younossi, Z. M., Wong, V. W., Tsochatzis, E. A., Castéra, L., Betel, M., Henry, L. L., & Zelber‐Sagi, S. (2025) · Liver International · doi:10.1111/liv.70311 · Cited by 12
Non-Invasive Diagnostic of NAFLD in Type 2 Diabetes Mellitus and Risk Stratification: Strengths and Limitations
Boeriu, A. M., Dobru, D. E., & Fofiu, C. (2023) · Life · doi:10.3390/life13122262 · Cited by 9
Predicting Hepatic Decompensation in Patients With Metabolic Dysfunction Associated Steatotic Liver Disease‐Related Cirrhosis: The ABID ‐ LSM Model
Bertot, L. C., Sòria, A., Jiménez-Masip, A., Serra, I., Broquetas, T., Vergara, M., Rodríguez-Castellano, A., Aracil, C., Maimouni, C. E., Muñoz, S., et al. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70215 · Cited by 8
Liver Stiffness Is a Predictor of Rebleeding in Patients With Hepatitis B-Related Cirrhosis: A Real-World Cohort Study
Liu, L., Nie, Y., Zhang, Y., Liu, Q., & Zhu, X. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.690825 · Cited by 8

Authors: Petta, S., Sebastiani, G., Viganò, M., Ampuero, J., Wai-Sun Wong, V., Boursier, J., Berzigotti, A., Bugianesi, E., Fracanzani, A. L., Cammà, C., Enea, M., Grottes, M. D., Di Marco, V., Younes, R., Keyrouz, A., Mazzola, S., Mendoza, Y., Pennisi, G., Romero-Gomez, M., Craxì, A., & de Ledinghen, V.
Affiliations: University of Palermo (IT)
McGill University Health Centre (CA)
University of Milan (IT)
Instituto de Biomedicina de Sevilla (ES)
University of Bern (CH)
University of Turin (IT)
Inserm (FR)
Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone" di Palermo (IT)
Corresponding author: Petta, Salvatore
ORCID: Petta, Salvatore
Sebastiani, Giada
Viganò, Mauro
Ampuero, Javier
Berzigotti, Annalisa
Bugianesi, Elisabetta
Fracanzani, Anna Ludovica
Cammà, Calogero
Enea, Marco
Younes, Ramy
Mazzola, Sergio
Mendoza, Yuly
Pennisi, Grazia
Venue: Clinical Gastroenterology and Hepatology
Publisher: Elsevier BV
Published: 2021-04
Volume: 19
Issue: 4
Pages: 806-815.e5
ISSN: 1542-3565 (ISSN-L)
DOI: 10.1016/j.cgh.2020.06.045
OpenAlex: W3038330698
Cited by: 197
References: 34
Citations by year: 2026: 26 · 2025: 32 · 2024: 45 · 2023: 38 · 2022: 27 · 2021: 25
FWCI: 16.84
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: Clinical Gastroenterology and Hepatology (publishedVersion)
PubMed (publishedVersion)
Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
RISalud Institutional Health Repository of Andalucía (submittedVersion, other-oa)
HAL (submittedVersion)
Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
BORIS (University Library Bern) (submittedVersion, other-oa)
DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion)
Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
Open Access CRIS of the University of Bern
Funders: Fonds de Recherche du Québec - Santé (267806, 27127)
Topics: Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
Keywords: non-alcoholic fatty liver disease, compensated advanced chronic liver disease, liver stiffness, transient elastography, liver fibrosis, hepatic decompensation, hepatocellular carcinoma, liver-related mortality, extrahepatic complications, liver-related events, risk stratification, variceal bleeding, ascites, encephalopathy
MeSH terms: Esophageal and Gastric Varices, Gastrointestinal Hemorrhage, Carcinoma, Hepatocellular, Humans, Liver, Liver Cirrhosis, Liver Neoplasms, Retrospective Studies, Elasticity Imaging Techniques, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver Disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks